52nd week of 2015 patent applcation highlights part 22 |
Patent application number | Title | Published |
20150368232 | LAMIVUDINE SALTS - The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection. | 2015-12-24 |
20150368233 | CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT - Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that I | 2015-12-24 |
20150368234 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS - A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. | 2015-12-24 |
20150368235 | Novel 2-Aminothiazole Derivative and Anti-Cancer Composition Comprising Same as Active Ingredient - The present invention relates to a novel 2-aminothiazole derivative, N-(5-(4-fluorophenyl)thiazole-2-il)-3-(furan-2-il)propane amide and to a use thereof as an anti-cancer drug. It is verified that the compound of the present invention has highly superior cancer cell-specific cytotoxic activity and in-vivo anti-cancer activity for inhibiting the growth of tumors in an animal model for cancer disease, and therefore can be developed as an anti-cancer candidate substance. | 2015-12-24 |
20150368236 | 2-(PYRIDIN-3-YL)-5-HETARYL-THIAZOLE COMPOUNDS CARRYING AN IMINE OR IMINE-DERIVED SUBSTITUENT FOR COMBATING INVERTEBRATE PESTS - The present invention relates to 2-(pyridin-3-yl)-5-hetaryl-thiazole compounds carrying an imine or imine-derived substituent on the 5-hetaryl ring which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes, and to a method for producing them. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds. | 2015-12-24 |
20150368237 | Heteroarylpiperidine and - piperazine derivatives as fungicides - Heteroarylpiperidine and -piperazine derivatives of the formula (I) | 2015-12-24 |
20150368238 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS - The present application relates to a series of substituted imidazo[1,2-a]pyridine compounds of formula (I), | 2015-12-24 |
20150368239 | PREPARATION OF NEMATOCIDAL SULFONAMIDES - Disclosed is a method for preparing a compound of Formula 1 by coupling of intermediates of Formula 2 and Formula 3 in the presence of an aluminum reagent of Formula 4 | 2015-12-24 |
20150368240 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS - The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis. | 2015-12-24 |
20150368241 | INHIBITORS OF HEMEPROTEIN-CATALYZED LIPID PEROXIDATION - Compounds, compositions and methods related to the prevention or treatment of isoprostane-mediated tissue damage in a mammalian subject in need thereof. | 2015-12-24 |
20150368242 | NOVEL TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVE - An object is to provide a novel compound having a higher MGAT2 inhibitory activity than conventional compounds. A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof is provided. | 2015-12-24 |
20150368243 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS - Provided herein are intermediates and processes useful for facile synthesis of biologically active molecules. | 2015-12-24 |
20150368244 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2015-12-24 |
20150368245 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR - To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. | 2015-12-24 |
20150368246 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I | 2015-12-24 |
20150368247 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS - The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. | 2015-12-24 |
20150368248 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS - This invention relates to novel 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, showing activity as specific inhibitors of growth and angiogenesis of hepatocellular carcinoma. The invention further includes pharmaceutical compositions containing the 2-substituted-6-biarylmethylamino-9-cyclopentylpurines. | 2015-12-24 |
20150368249 | FUSED RING PYRIMIDINE COMPOUND AND PEST CONTROL AGENT CONTAINING THE SAME - Provided is a pest control agent containing a fused ring pyrimidine compound represented by the following formula (I) or a salt thereof as an effective component. In formula (I), A represents a nitrogen atom or C—R | 2015-12-24 |
20150368250 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS - Imidazopyridazines of formula (I) | 2015-12-24 |
20150368251 | MACROCYCLIC MOLECULES AS HCV ENTRY INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2015-12-24 |
20150368252 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2015-12-24 |
20150368253 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2015-12-24 |
20150368254 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2015-12-24 |
20150368255 | HALOGENATED INDOLE AND BENZOFURAN DERIVATIVES OF ISOQUINUCLIDENE AND PROCESSES FOR PREPARING THEM - Provided herein are halogenated indole and benzofuran derivatives of isoquinuclidene and intermediates thereto, and processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (−) and (+) noribogaine, in substantially enantiomerically pure forms. | 2015-12-24 |
20150368256 | NEW BICYCLICPYRIDINE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 2015-12-24 |
20150368257 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions - This application relates to tricyclic compounds of Formula I: | 2015-12-24 |
20150368258 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS - The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents. | 2015-12-24 |
20150368259 | Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof - The present invention relates to the field of medicinal chemistry, and in particular relates to 4-(five-membered heterocyclic pyrimidine/pyridine substituted) amino-1H-3-pyrazolecarboxamide derivatives, the preparation method thereof, pharmaceutical compositions containing these compounds and the medicinal use thereof, especially as protein kinase inhibitors for anti-tumour use. | 2015-12-24 |
20150368260 | AMINO-SUBSTITUTED ISOTHIAZOLES - The present invention relates to isothiazoles of general formula (I) which inhibit the mitotic checkpoint: in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. | 2015-12-24 |
20150368261 | CONJUGATES AND SMALL MOLECULES WHICH INTERACT WITH THE CD16A RECEPTOR - The invention is related to medicine, in particular, to oncology and immunology. The novel compounds of the general formula 1 or 2, exhibiting affinity for CD16a receptor have been proposed. There were also proposed novel modified proteins active towards CD16a receptor, selected from antibody or autogen conjugated by a modifying compound selected from compound of the general formula 1 or 2, which stimulate and direct antibody-dependent cellular cytotoxicity. The novel modified proteins (conjugates) could be used for destruction of definite targeted group of cells in organism, for example, cancerous cells or autoimmune lymphocytes. There were also proposed methods for conjugate preparation, pharmaceutical composition, and medicament, comprising modified proteins for treating oncology and autoimmune diseases. | 2015-12-24 |
20150368262 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO - Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed. | 2015-12-24 |
20150368263 | PHARMACEUTICAL FORMULATIONS CONTAINING 3-(4-CINNAMYL-L-PIPERAZINYL) AMINO DERIVATIVES OF 3-FORMYLRIFAMYCIN SV AND 3-FORMYLRIFAMYCIN S AND A PROCESS OF THEIR PREPARATION - The present invention related to a process of preparation of pharmaceutically acceptable formulations containing as active substance 3-(4-cinnamyl-1-piperazinyl)-amino derivatives of 3-formylrifamycine SV and 3-formylrifamycine S, which possess high activity against Gram-positive and Gram-negative microorganisms, as well as against tuberculous micobacteria (including atypical and rifamycin resistant), and to a method for the preparation of 3-(4-cinnamyl-1-piperazinyl)-amino derivatives of 3-formylrifamycine SV and 3-formylrifamycine S. The method for the preparation of pharmaceutical compositions is readily feasible, and does not require special equipment for its implementation. The process for preparing the compounds is characterized by high yield and purity, using an environmental clean solvent-ethanol and water in the preparation and isolation of substances, and the absence of residual organic solvents in the final product. | 2015-12-24 |
20150368264 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS - Methods of making compounds of Formula I are disclosed: | 2015-12-24 |
20150368265 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I | 2015-12-24 |
20150368266 | CHEMICAL COMPOUNDS 542 - The present invention relates to compounds of Formula (I): | 2015-12-24 |
20150368267 | MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2015-12-24 |
20150368268 | PLYMOREPHOUS FORMS III AND IV OF N-BENZOYL - STAUROSPORINE - The present invention relates to a crystalline form III and a crystalline form IV of N-benzoyl staurosporine. | 2015-12-24 |
20150368269 | Factor IXa Inhibitors - The present invention provides a compound of Formula (I) | 2015-12-24 |
20150368270 | FLAP MODULATORS - The present invention relates to compounds of Formula (I), or a form thereof wherein ring A, R | 2015-12-24 |
20150368271 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR - Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor. | 2015-12-24 |
20150368272 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE - To provide a liquid crystal compound satisfying at least one physical property such as high stability to light, a high clearing point, low minimum temperature of a liquid-crystal phase, small viscosity, suitable optical anisotropy, large dielectric anisotropy, a large dielectric constant in a minor axis direction, a suitable elastic constant, excellent compatibility with other liquid crystal compounds. The compound is represented by formula (1-1): | 2015-12-24 |
20150368273 | IMIDAZO PYRIDINE COMPOUNDS - The present invention provides compounds of the formula I, wherein X is a bond or CH | 2015-12-24 |
20150368274 | Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof - The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction. | 2015-12-24 |
20150368275 | NOVEL FLUOROERGOLINE ANALOGS - Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2015-12-24 |
20150368276 | VAPOCHROMIC COORDINATION POLYMERS FOR USE IN ANALYTE DETECTION - Vapochromic coordination polymers useful for analyte detection are provided. The vapochromism may be observed by visible color changes, changes in luminescence, and/or spectroscopic changes, for example in the infrared (IR) or Raman signatures. One or more of the above chromatic changes may be relied upon to identify a specific analyte, such as a volatile organic compound or a gas. The chromatic changes may be reversible to allow for successive analysis of different analytes. The coordination polymer has the general formula M | 2015-12-24 |
20150368277 | PREPARATION OF ALKALINE EARTH METAL-COMPLEXED METAL BISAMIDES FROM METAL MONOAMIDES - The present invention relates to a process for preparing alkaline earth metal-complexed metal bisamides of the formula (I) from metal monoamides of the formula (II). The present invention further relates to a process for preparing alkaline earth metal monoamides of the formula (II-AE), to novel LiCl-free alkaline earth metal monoamides of the formula (II-AE-L), and to the use of these alkaline earth metal monoamides for metallation of aromatics, heteroaromatics, alkenes, alkynes and other organic compounds having activated C—H bonds. | 2015-12-24 |
20150368278 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE - The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. | 2015-12-24 |
20150368279 | COMPOUND, DRYING AGENT, SEALING STRUCTURE, AND ORGANIC EL ELEMENT - A compound represented by formula (1) is provided: | 2015-12-24 |
20150368280 | HIGH REFRACTIVE INDEX ACRYLIC COMPOUND AND METHOD FOR PREPARING THE SAME - An acrylic compound is represented by Formula 1. | 2015-12-24 |
20150368281 | Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino - Disclosed are a class of platinum compounds of malonic acid derivatives having a leaving group containing an amino or alkylamino, and pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition containing the compounds. Also disclosed are uses of the compounds for treating cell proliferative diseases especially cancers. The platinum compounds of the present invention have high solubility in water, low toxicity and strong anti-tumor effect. | 2015-12-24 |
20150368282 | COBALT-CONTAINING COMPOUNDS, THEIR SYNTHESIS, AND USE IN COBALT-CONTAINING FILM DEPOSITION - Cobalt-containing compounds, their synthesis, and their use for the deposition of cobalt containing films are disclosed. The disclosed cobalt-containing compounds have one of the following formulae: wherein each of R | 2015-12-24 |
20150368283 | D-FAGOMINE FOR THE CONTROL OF INFLAMMATORY PROCESSES RELATED TO AN OVERACTIVATION OF THE HUMORAL IMMUNE RESPONSE - The present invention belongs to the field of nutraceuticals or functional agents with immunostimulating capacity for triggering mechanisms of the innate immune response at a mucosal level. More specifically, it refers to the use of the compound | 2015-12-24 |
20150368284 | Surfactant - Described is an di(alkyl-glycoside) sulfomethylsuccinate having the formula R | 2015-12-24 |
20150368285 | Compound Extracted From Husk And Fruit Stem Of Xanthoceras Sobifolia And Its Extracting Method And Use Thereof - This invention relates to the compound extracted from husk and fruit stem of | 2015-12-24 |
20150368286 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are methods of preparing a phosphoroamidate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections. | 2015-12-24 |
20150368287 | NUCLEOSIDE AND NUCLEOTIDE HAVING NITROGEN-CONTAINING HETEROCYCLE STRUCTURE - The present invention provides compounds shown by the formula: | 2015-12-24 |
20150368288 | METHOD OF PREPARING OLIGOMERIC COMPOUNDS USING MODIFIED COUPLING PROTOCOLS - Provided herein are methods for the synthesis of oligomeric compounds wherein the standard coupling protocols are modified when coupling bicyclic nucleosides of Formula I. More particularly, the modified coupling protocols provide for a decrease in the ratio of phosphoramidite solution to activator solution in the coupling reagent with an increased contact time. The modified coupling protocols provide for oligomeric compounds having comparable yields to similar oligomeric compounds having modified nucleosides other than bicyclic nucleosides of Formula I. | 2015-12-24 |
20150368289 | Protopanoxadiol derivative, preparation method thereof and application thereof - The present invention provides a protopanoxadiol derivative of structural formula I or II, a preparation method and an application thereof. The present invention performs structural modification on protopanoxadiol, and obtains multiple novel compounds with unique structures. As confirmed in vivo pharmacological experiments, these compounds have stronger anti-depression activity, can be used as an active ingredient in preparing medicine for preventing or treating depression-type mental illness, and have wide use and development prospect, | 2015-12-24 |
20150368290 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME - This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from | 2015-12-24 |
20150368291 | N-acetyl amino acid ESTER derivatives of Betulin and preparation method thereof - The present invention disclosed N-acetyl amino acid ester derivatives of betulin and the preparation method thereof, the method comprising the steps that in the presence of an alkaline substance, a catalyst and a racemization-inhibitor, the carboxyl group of N-acetyl amino acid is activated by a coupling agent; and then the activated N-acetyl amino acid is reacted with betulin via esterification reaction to obtain the N-acetyl amino acid ester derivative of betulin. The present invention provided a simple synthesis method to synthesize the N-acetyl amino acid ester derivatives of betulin by using betulin as a precursor compound and modifying the molecular structure of betulin. Such structural modification of betulin significantly enhances the anti-tumor activity of the betulin derivatives and therefore has important values. | 2015-12-24 |
20150368292 | METHOD OF PRODUCING A PROTEIN - The present invention relates to a method of producing a recombinant protein by harvesting a microbial cell broth and adding an amount of a flocculant to achieve an effective particle size distribution. The present invention also relates to a method of clarifying a microbial harvest by adding an amount of a flocculant to achieve an effective particle size distribution. | 2015-12-24 |
20150368293 | METHOD FOR FRACTIONATING SOLUBLE FRACTIONS OF PEAS, FRACTION THUS OBTAINED AND UPGRADE THEREOF - A method for fractionating soluble fractions of peas, includes, in sequence, a step of microfiltering or centrifuging, followed by a step of ultrafiltering, and optionally a reverse-osmosis step. A reduction of the leakage of proteins toward the soluble fractions, an improvement of the yield of the single concentration step by evaporating the soluble fractions, and the selective isolation of proteins of interest are thus achieved. The method is easy to implement, the devices used at each single step are conventional and well known to the person skilled in the art. Also, the method does not use any organic solvent other than water. | 2015-12-24 |
20150368294 | GADD45BETA TARGETING AGENTS - Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders. | 2015-12-24 |
20150368295 | METHOD FOR PRODUCING PYRAZOLES, NOVEL PYRAZOLES AND APPLICATIONS THEREOF - A method for preparing a pyrazole of formula (I) in which R,R′ and R″ have different meanings, characterised in that it involves reacting a sydnone of formula (II) in which R and R′ have the meanings already indicated, with an alkyne of formula (III) in which R″ has the meaning already indicated, in the presence of copper, to obtain a pyrazole compound of formula (I) that is then isolated and salified if desired. | 2015-12-24 |
20150368296 | Method for preventing or treating heart diseases by using a composition containing an isolated peptide - This present invention discloses an isolated peptide which amino acid sequence is SEQ ID NO.:1. The isolated peptide can inhibit the expressions of signal transduction proteins related to the heart hypertrophy pathway, apoptosis of myocardial cells related proteins, and cardiac fibrosis related proteins to have effects of preventing such as apoptosis of myocardial cells, cardiac fibrosis, heart hypertrophy, cardiac inflammation or other heart diseases. Therefore, the peptide disclosed in this present invention can be an active ingredient of pharmaceutical composition to have effects for preventing or treating cardiovascular diseases. | 2015-12-24 |
20150368297 | Novel Peptide Compound for Inhibiting Restenosis and Promoting Re-Endothelialization and Method for Preparing the Same - Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent. | 2015-12-24 |
20150368298 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2015-12-24 |
20150368299 | AMYLOID-BETA BINDING PROTEINS - The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any β form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided. | 2015-12-24 |
20150368300 | COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS - The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia. | 2015-12-24 |
20150368301 | PEPTIDE INHIBITOR OF NOX1 NADPH OXIDASE - An isolated peptide or fusion having the peptide useful to interfere with the phosphorylation of Nox1, block or inhibit binding of NoxA1 activation domain (AD) to Nox1, and/or prevent or inhibit assembly of the p47phox/NoxA1 complex with Nox1, or a vector encoding the peptide or fusion thereof, and methods of using the peptide, fusion or vector are provided. | 2015-12-24 |
20150368302 | DESIGNED ANKYRIN REPEAT PROTEINS BINDING TO PLATELET-DERIVED GROWTH FACTOR - New designed ankyrin repeat proteins with binding specificity for PDGF-BB are described, as well as nucleic acids encoding such PDGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases. | 2015-12-24 |
20150368303 | Flagellin Fusion Proteins and Use Thereof to Induce Immune Responses Against Pseudomonas Aeruginosa - The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a | 2015-12-24 |
20150368304 | NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B - The invention provides proteins from group B | 2015-12-24 |
20150368305 | AXMI218, AXMI219, AXMI220, AXMI226, AXMI227, AXMI228, AXMI229, AXMI230 AND AXMI231 DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:13-30, or the nucleotide sequence set forth in SEQ ID NO:1-12, as well as variants and fragments thereof. | 2015-12-24 |
20150368306 | ACID-RESISTANT YEAST CELL WITH REDUCED FPS1 ACTIVITY AND METHOD OF PRODUCING LACTATE BY USING THE YEAST CELL - Provided are an acid-resistant yeast cell with genetic modification and reduced Fps1 activity compared to that of a parent cell without the genetic modification; and a method of producing lactate by using the yeast cell. | 2015-12-24 |
20150368307 | LENTIVIRAL VECTOR BASED IMMUNOLOGICAL COMPOUNDS AGAINST MALARIA - The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of a | 2015-12-24 |
20150368308 | METHOD OF PREPARING A KERATIN-BASED BIOMATERIAL AND KERATIN-BASED BIOMATERIAL FORMED THEREOF - Method of preparing a keratin-based biomaterial is provided. The method comprises a) reacting keratin with a polymer having at least one of an amine and carboxylic functional group in the presence of a carbodiimide cross-linking agent to form a cross-linked keratin-polymer material; and b) freeze drying the cross-linked keratin-polymer material to form the keratin-based bio-material. A keratin-based biomaterial thus prepared is also provided. | 2015-12-24 |
20150368309 | PLACENTA GROWTH FACTOR IN TREATING DUCHENNE MUSCULAR DYSTROPHY - The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant PLGF protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset. The present invention also provides exemplary recombinant PLGF proteins including monomeric, dimeric and single-chain PLGF proteins. | 2015-12-24 |
20150368310 | ANALOGS OF GLUCAGON EXHIBITING GIP RECEPTOR ACTIVITY - Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range. | 2015-12-24 |
20150368311 | Exendin-4 Derivatives as Selective Glucagon Receptor Agonists - The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia. | 2015-12-24 |
20150368312 | INSULIN SECRETING POLYPEPTIDES - This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided. | 2015-12-24 |
20150368313 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 2015-12-24 |
20150368314 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues. | 2015-12-24 |
20150368315 | Nucleic acids encoding rage fusion proteins - The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE). | 2015-12-24 |
20150368316 | A SELECTIVE HIGH-AFFINITY IMMUNE STIMULATORY REAGENT AND USES THEREOF - Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection. | 2015-12-24 |
20150368317 | METHODS RELATED TO CTLA4-FC FUSION PROTEINS - The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept. | 2015-12-24 |
20150368318 | MUTANTS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF - The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide, or a fusion of a said derivative thereof, wherein the polypeptide, fusion or derivative retains a biological activity of wild type IL-IRa. In one embodiment, the isolated polypeptide, fusion or derivative is or comprises a polypeptide variant of amino acid sequence SEQ ID NO: 1 comprising or consisting of substitutions at one or more of the following amino acid mutations of SEQ ID NO: 1: Q29K, P38Y, P38R, L42W, D47N, E52R, H54R, E90Y, Q129L, Q129N, M136N, M136D and Q149K. Also provided are pharmaceutical compositions of the above polypeptide, fusion or derivative, as well as uses of the same for treating a disease or condition capable of being treated by an agent which inhibits the function of IL-1 receptors. | 2015-12-24 |
20150368319 | FIBRONECTIN TYPE III DOMAIN PROTEINS WITH ENHANCED SOLUBILITY - Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target. | 2015-12-24 |
20150368320 | Polyclonal Antibodies Against Clostridium Difficile and Uses Thereof - A polyclonal antibody composition prepared from eggs of immunized hens is used to treat | 2015-12-24 |
20150368321 | NOVEL FULL SPECTRUM ANTI-DENGUE ANTIBODY - The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV. | 2015-12-24 |
20150368322 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE - Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2015-12-24 |
20150368323 | ANTI-STAPHYLOCOCCAL ANTIBODIES - This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof. | 2015-12-24 |
20150368324 | MODULATION OF SYNAPTIC MAINTENANCE - C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease. | 2015-12-24 |
20150368325 | MODULATION OF SYNAPTIC MAINTENANCE - C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease. | 2015-12-24 |
20150368326 | MODULATION OF SYNAPTIC MAINTENANCE - C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease. | 2015-12-24 |
20150368327 | ANTI-SEMAPHORIN 3A ANTIBODY AND TREATMENT OF ALZHEIMER'S DISEASE AND INFLAMMATORY IMMUNE DISEASES USING SAME - The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease. | 2015-12-24 |
20150368328 | Immunotherapy for Clearing Pathological Tau Conformers - The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject. | 2015-12-24 |
20150368329 | Methods of Treating Ocular Diseases - The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating ocular diseases. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit ocular neovascularization. | 2015-12-24 |
20150368330 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75 - This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. | 2015-12-24 |
20150368331 | ANGIOPOIETIN-RELATED PROTEIN 4 (CANGPTL4) AS A DIAGNOSTIC BIOMARKER FOR ACUTE LUNG DAMAGE - The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia. | 2015-12-24 |